GSK drops oncology and DMD assets

Published: 28 April 2021

GlaxoSmithKline removes two phase I assets from its pipeline due to “portfolio prioritisation.”

GSK3537142 (NYESO-ImmTAC) is an anti-CD3 bispecific antibody which was being tested in solid tumors and synovial sarcoma, and GSK3439171 is a hematopoietic prostaglandin D2 synthase inhibitor which was intended to treat Duchenne muscular dystrophy (DMD). 

Both candidates were “removed from the phase I pipeline due to portfolio prioritization”, according to information released by the company.